

ONLINE SEARCH REQUEST FORM

USER Shap Rose SERIAL NUMBER 753907

ART UNIT 125 PHONE 308-7602 DATE 3/3/92

Please give a detailed statement of requirements. Describe as specifically as possible the subject matter to be searched. Define any terms that may have special meaning. Give examples or relevant citations, authors, or keywords, if known.

You may include a copy of the broadest and or relevant claim(s).

In each of Cas Online, Derwent, ^{and 1989 on online only in} ~~Biosis & Medline~~
print full with abstracts please

I a fluticasone or fluticasone propionate
~ RN 80474-14-2

~ RN 136112-02-02

I_a print out all entries on I } L4

I_b with one of: asthma or inhalation or metered dose L5-3
~ inhaler or aerosol

II print out all entries of I

with salmeterol ~ RN 89365-50-4 } L9-3

III print out all entries of I with salbutamol ~ its RN } L10-2

IV print out Family of Patents for Derwent for

GT.BR. 2 088877 → CAN 96(19)H3044p

GT.BE 2 140800

102(11)095383p

V Find abstracts in Chemabstracts for IV (or family members)
~ print out

CAS ONLINE

STAFF USE ONLY

COMPLETED

3-6-92

SEARCHER

JOHN DANZMAN

ONLINE TIME

29 TOTAL TIME 39

(in minutes)

NO. OF DATABASES

1

SYSTEMS

☒ CAS ONLINE

☐ DARC/QUESTEL

☐ DIALOG


☐ SDC

☐ OTHER

FILE 'REGISTRY' ENTERED AT 12:47:20 ON 06 MAR 92
 USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
 COPYRIGHT (C) 1992 AMERICAN CHEMICAL SOCIETY (ACS)

STRUCTURE FILE UPDATES: HIGHEST RN 139341-64-3
 DICTIONARY FILE UPDATES: 29 FEB 92 (920229/ED) HIGHEST RN 139311-38-9


L1 ANSWER 1 OF 1 COPYRIGHT 1992 ACS
 RN 90566-53-3
 CN Androsta-1,4-diene-17-carbothioic acid, 6,9-difluoro-11,17-dihydroxy-
 16-methyl-3-oxo-, S-(fluoromethyl) ester,
 (6.alpha.,11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)
 CN Fluticasone
 MF C22 H27 F3 O4 S
 LC CA, PHAR, WHO
 STE 4:6A,11B,16A,17A.ANDROST




2 REFERENCES IN FILE CA (1967 TO DATE)

=> d 12

L2 ANSWER 1 OF 1 COPYRIGHT 1992 ACS
 RN 80474-14-2
 CN Androsta-1,4-diene-17-carbothioic acid, 6,9-difluoro-11-hydroxy-16-
 methyl-3-oxo-17-(1-oxopropoxy)-, S-(fluoromethyl) ester,
 (6.alpha.,11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)
 CN Fluticasone propionate
 MF C25 H31 F3 O5 S
 CI COM
 LC BIOSIS, CA, CIN, MEDLINE, PHAR
 STE 4:6A,11B,16A,17A.ANDROST





CM 2

CRN 94749-08-3


CMF C25 H37 N 04 . C11 H8 03

CM 3

CRN 89365-50-4

CMF C25 H37 N 04

CSTE 3: (+)



Page 1-A


.....Ph

Page 1-B

CM 4

CRN 86-48-6

CMF C11 H8 03



C: . C. : C
: . :
C C

1 REFERENCES IN FILE CA (1967 TO DATE)

=>

=>

=> fil ca

FILE 'CA' ENTERED AT 12:49:40 ON 06 MAR 92

USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT

COPYRIGHT (C) 1992 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1967 - 21 FEB 92 (920221/ED) VOL 116 ISS 08.

For OFFLINE Prints or Displays, use the ABS or ALL formats to obtain abstract graphic structures. The AB format DOES NOT display structure diagrams.

=> fil reg

FILE 'REGISTRY' ENTERED AT 12:51:12 ON 06 MAR 92

USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT

COPYRIGHT (C) 1992 AMERICAN CHEMICAL SOCIETY (ACS)

STRUCTURE FILE UPDATES: HIGHEST RN 139341-64-3

DICTIONARY FILE UPDATES: 29 FEB 92 (920229/ED) HIGHEST RN 139311-38-9

=> s salmeterol/cn

L6 1 SALMETEROL/CN

=> d

L6 ANSWER 1 OF 1 COPYRIGHT 1992 ACS

RN 89365-50-4

CN 1,3-Benzenedimethanol, 4-hydroxy-.alpha.1-[[[6-(4-phenylbutoxy)hexyl]amino]methyl]-, (.+-.)- (9CI) (CA INDEX NAME)

CN Salmeterol

DR 94749-03-8

MF C25 H37 N O4

CI COM

LC BIOSIS, CA, CIN, MEDLINE, PHAR, WHO

STE 3:(+-)

OH

.

.

.

.

.

: C. . CHCH2.....NH.....(CH2)6O....(CH2)4.

C : . C .

. :

. :

. :

. C : . C

: C.

CH2.....OH


Page 1-A
.....Ph

Page 1-B
14 REFERENCES IN FILE CA (1967 TO DATE)

=
=> s salbutamol/cn
L8 1 SALBUTAMOL/CN

=> d

L8 ANSWER 1 OF 1 COPYRIGHT 1992 ACS
RN 18559-94-9
CN 1,3-Benzenedimethanol, .alpha.1-[[(1,1-dimethylethyl)amino]methyl]-4-
hydroxy- (9CI) (CA INDEX NAME)
CN Salbutamol
CN m-Xylene-.alpha.,.alpha.'-diol, .alpha.1-[(tert-butylamino)methyl]-4-
hydroxy- (8CI)
CN AH 3365
CN Albuterol
CN Aerolin
CN Sultanol
CN Ventolin
CN Saventol
FS 3D CONCORD
MF C13 H21 N O3
CI COM
LC ANABSTR, BEILSTEIN, BIOSIS, CA, CASREACT, CIN, CJACS, CSChem, CSNB,
ETNECS, IFICDB, IFIPAT, IFIUD8, MEDLINE, PHAR, RTECS, WHO



1218 REFERENCES IN FILE CA (1967 TO DATE)

=> fil ca
FILE 'CA' ENTERED AT 12:52:30 ON 06 MAR 92
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
COPYRIGHT (C) 1992 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1967 - 21 FEB 92 (920221/ED) VOL 116 ISS 08.
For OFFLINE Prints or Displays, use the ABS or ALL formats to obtain
abstract graphic structures. The AB format DOES NOT display structure
diagrams.

FILE 'REGISTRY' ENTERED AT 12:47:20 ON 06 MAR 92

E FLUTICASONE/CN

L1 1 S E3

L2 1 S E4

FILE 'REGISTRY' ENTERED AT 12:48:29 ON 06 MAR 92

L3 1 S E5

FILE 'CA' ENTERED AT 12:49:40 ON 06 MAR 92

L4 5 S (FLUTICASONE#/IA OR L1 OR L2 OR L3)

L5 3 S L4 AND (ASTHMA? OR INHAL? OR DOSE# OR AEROSOL?)/IA

FILE 'CA' ENTERED AT 12:51:09 ON 06 MAR 92

FILE 'REGISTRY' ENTERED AT 12:51:12 ON 06 MAR 92

L6 1 S SALMETEROL/CN

L7 0 S SALBUTANOL/CN

L8 1 S SALBUTAMOL/CN

FILE 'CA' ENTERED AT 12:52:30 ON 06 MAR 92

L9 3 S L4 AND (SALMETEROL?/IA OR L6)

L10 2 S L4 AND (SALBUTAMOL?/IA OR L8)

=> d 14 1-5 all;d 15 1-3;d 19 1-3;d 110 1-2

L4 ANSWER 1 OF 5 COPYRIGHT 1992 ACS

AN CA115(18):189788v

TI Hydrofluorocarbon propellants for pharmaceutical aerosols

AU Steele, Gerald; Somani, Asit; Lim, Joseph Geok Paan

CS Fisons PLC

LO UK

SO PCT Int. Appl., 18 pp.

PI WO 9111173 A1 8 Aug 1991

DS W: CA, JP, US

RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, NL, SE

AI WO 91-GB133 30 Jan 1991

PRAI GB 90-2351 2 Feb 1990

GB 90-23655 31 Oct 1990

GB 90-26476 5 Dec 1990

IC ICM A61K009-12

ICS A61K009-72

SC 63-6 (Pharmaceuticals)

DT P

CO PIXXD2

PY 1991

LA Eng

AB A pressurized aerosol compn. comprises a liquefied hydrofluorocarbon propellant contg. substantially no nonhydrofluorocarbon solvent having dispersed therein a medicament and a fluorinated surfactant. The propellants are substantially taste- and odor-free and have suitable vapor pressures for the administration of medicaments by inhalation, yet are environmentally safe and acceptable. Thus, a compn. contg. nedocromil Na 0.200, FC 431 (fluorinated acrylic polymer) 0.061, and CF3CFH2 11.979 g was filled into Al aerosol canister.

KW fluoro hydrocarbon propellant drug aerosol; nedocromil tetrachloroethane propellant aerosol

IT Bronchodilators

(aerosol of, hydrofluorocarbon propellants for)

IT Pharmaceutical dosage forms

(aerosols, inhalants, hydrofluorocarbon propellants in)

IT Hydrocarbons, biological studies

(fluoro, propellant for pharmaceutical aerosols)

IT 51-55-8, Atropine, biological studies 1944-12-3, Fenoterol

ALL 5 CITES

Fenoterol 15826-37-6, Sodium cromoglycate 18559-94-9, Salbutamol
 22254-24-6, Ipratropium bromide 23031-25-6, Terbutaline
 38677-81-5, Pirbuterol 51022-70-9, Salbutamol sulfate
 54063-54-6, Reproterol 69049-74-7, Nedocromil sodium 73573-87-2
 85197-77-9, Tipredane 89365-50-4 ***90566-53-3***
 . (aerosol of, hydrofluorocarbon propellants for)
 IT 75-37-6, 1,1-Difluoroethane 431-89-0 811-97-2,
 1,1,1,2-Tetrafluoroethane
 . (propellant for pharmaceutical aerosols)
 IT 11114-17-3, FC 430 12707-52-7, FC 431 25322-68-3, Polyethylene
 glycol 106392-12-5, Poloxamer
 (surfactant for pharmaceutical aerosols)

L4 ANSWER 2 OF 5 COPYRIGHT 1992 ACS
 AN CA115(14):142260b
 TI Pharmaceutical inhalants containing a bronchodilator and a steroidal
 anti-inflammatory agent
 AU Palmer, James Barry Douglas
 CS Glaxo Group Ltd.
 LO UK
 SO Eur. Pat. Appl., 8 pp.
 PI EP 416951 A1 13 Mar 1991
 DS R: AT, DE, DK, ES, GR, LU, NL, SE
 AI EP 90-309846 7 Sep 1990
 PRAI GB 89-20392 8 Sep 1989
 GB 89-23644 20 Oct 1989
 IC ICM A61K031-57
 ICI A61K031-57, A61K031-135
 SC 63-6 (Pharmaceuticals)
 DT P
 CO EPXXDW
 PY 1991
 LA Eng
 AB Pharmaceutical compns. for treatment of respiratory disorders
 comprise effective amts. of salmeterol (and/or a physiol. acceptable
 salt thereof) and fluticasone propionate for simultaneous,
 sequential, or sep. administration by inhalation. The compn.
 permits the establishment of a twice daily dosing regimen and shows
 greater efficiency and longer duration of bronchodilating activity
 than previously known combinations. Thus, a metered dose inhaler
 contained salmeterol 1-hydroxy-2-naphthoate 25.0, fluticasone
 propionate 25.0, stabilizer 5.0 .mu.g, CCl3F 23.70, and CCl2F2 61.25
 mg per actuation.
 KW respiratory disease salmeterol fluticasone inhalant
 IT Respiratory tract
 (disease, treatment of, by inhalation of salmeterol and
 fluticasone propionate combination)
 IT Pharmaceutical dosage forms
 (inhalants, of salmeterol and fluticasone propionate combination,
 for respiratory disorder treatment)
 IT Pharmaceutical dosage forms
 (powders, inhalants, of salmeterol and fluticasone propionate
 combination, for respiratory disorder treatment)
 IT 136112-01-1 ***136112-02-2***
 (pharmaceutical inhalants contg., for respiratory disorder
 treatment)

L4 ANSWER 3 OF 5 COPYRIGHT 1992 ACS
 AN CA114(20):192593n
 TI Nonphospholipid pharmaceutical liposomes
 AU Radhakrishnan, Ramachandran
 CS Liposome Technology, Inc.
 LO USA
 SO PCT Int. Appl., 96 pp.
 PI WO 9006775 A1 28 Jun 1990

RW: AT, BE, CH, DE, ES, FR, GB, IT, LU, NL, SE
 AI WD 89-US5525 6 Dec 1989
 PRAI US 88-284158 14 Dec 1988
 US 88-284216 14 Dec 1988
 IC A61K043-00; A61K049-00; A61K037-22
 SC 63-6 (Pharmaceuticals)
 SX 1
 DT P
 CO PIXXD2
 PY 1990
 LA Eng
 AB A nonconventional liposome comprn. consisting of nonphospholipid lipids, esp. cholesterol and cholesterol ester salts, are used for encapsulation of drugs. They are useful for sustained release of steroids, and are suitable for treatment of inflammatory, arthritic, rheumatoid diseases, etc., esp. as aerosols for interstitial lung disease. Beclomethasone dipropionate (I) 10 was incorporated into liposomes prepd. with Na cholesterol sulfate 50 and cholesterol 40 mol %. Sustained release of I was obsd. in rats following intratracheal administration, in contrast to liposomes formulated with phosphatidylcholine and cholesterol.
 KW nonphospholipid sustained release liposome pharmaceutical;
 interstitial lung disease liposome aerosol; steroid nonphospholipid sustained release liposome
 IT Micelles
 (nonphospholipid pharmaceutical)
 IT Lipids, biological studies
 (nonphospholipid, pharmaceutical liposomes of)
 IT Allergy inhibitors
 Neoplasm inhibitors
 Steroids, biological studies
 (nonphospholipid liposomes contg.)
 IT Interferons
 Vaccines
 (pharmaceutical liposomes contg. cholesterol and salt of cholesterol ester and)
 IT Gonadotropins
 (pharmaceutical liposomes contg. cholesterol and salt of cholesterol ester and)
 IT Lung, disease or disorder
 Skin, disease or disorder
 (treatment of, nonphospholipid pharmaceutical liposomes for)
 IT Haemophilus influenzae
 Streptococcus pneumoniae
 (vaccines, pharmaceutical liposomes contg. cholesterol and salt of cholesterol ester and)
 IT Pharmaceutical dosage forms
 (aerosols, liposomes, nonphospholipid liposomes in)
 IT Inflammation inhibitors
 (antiarthritics, nonphospholipid liposomes contg.)
 IT Inflammation inhibitors
 (antirheumatics, nonphospholipid liposomes contg.)
 IT Virus, animal
 (human immunodeficiency, vaccines, pharmaceutical liposomes contg. cholesterol and salt of cholesterol ester and)
 IT Lymphokines and Cytokines
 (interleukin 2, pharmaceutical liposomes contg. cholesterol and salt of cholesterol ester and)
 IT Lung, disease or disorder
 (interstitial, treatment of, nonphospholipid pharmaceutical liposomes for)
 IT Pharmaceutical dosage forms
 (liposomes, cholesterol and cholesterol ester salts in)
 IT Pharmaceutical dosage forms
 (liposomes, topical, nonphospholipid liposomes in)
 IT Antibiotics

(monoclonal, pharmaceutical liposomes contg. cholesterol and salt of cholesterol ester and)

IT Virus, animal
(respiratory syncytial, vaccines, pharmaceutical liposomes contg. cholesterol and salt of cholesterol ester and)

IT Globulins, biological studies
(.gamma.-, pharmaceutical liposomes contg. cholesterol and salt of cholesterol ester and)

IT 57-88-50, Cholesterol, esters, salts 2864-50-8 6614-96-6
24352-55-4 99523-97-4 107745-49-3 107745-53-9 133058-04-5
133058-05-6 133161-25-8 133161-26-9 133352-85-9 133352-86-0
133442-36-1 133442-37-2 133442-38-3
(pharmaceutical liposomes contg. cholesterol and)

IT 50-02-2, Dexamethasone 50-07-7, Mitomycin 50-18-0,
Cyclophosphamide 50-23-7, Hydrocortisone 50-24-8, Prednisolone
51-41-2, Norepinephrine 51-43-4, Adrenaline 51-61-6, Dopamine,
biological studies 51-64-9, Dextroamphetamine 52-39-1,
Aldosterone 52-53-9, Verapamil 52-88-0, Atropine methyl nitrate
53-03-2, Prednisone 53-06-5, Cortisone 53-33-8, Paramethasone
57-22-7 57-42-1, Demerol 58-55-9, Theophylline, biological
studies 58-73-1, Diphenhydramine 59-05-2, Methotrexate 60-54-8
61-33-6, biological studies 64-85-7, Deoxycortone 68-88-20,
Hydroxyzine, derivs. 71-68-1, Dilaudid 76-41-5, Oxymorphone
83-43-2, Methylprednisolone 86-54-4, Apresoline 91-81-6,
Pyribenzamine 100-33-4, Pentamidine 113-92-8, Chlorpheniramine
114-07-8, Erythromycin 124-94-7, Triamcinolone 127-31-1,
Fluorocortisone 152-97-6 153-61-7, Cephalothin 299-42-3,
Ephedrine 317-34-0 356-12-7, Fluocinonide 378-44-9,
Betamethasone 426-13-1, Fluorometholone 446-86-6, Azathioprine
638-94-8, Desonide 645-05-6, Altretamine 671-16-9, Procarbazine
768-94-5, Amantadine 807-38-5, Fluocinolone 1110-40-3,
Cortivazol 1247-42-3, Meprednisone 1397-89-3, Amphotericin B
1403-66-3, Gentamycin 1404-90-6, Vancomycin 1524-88-5,
Flurandrenolone 2135-17-3 2607-06-9 2668-66-8, Medrysone
3093-35-4, Halcinonide 3385-03-3, Flunisolide 3693-38-7,
Fluclorolone 3778-73-2 4419-39-0, Beclomethasone 4697-36-3,
Carbenicillin 5251-34-3, Cloprednol 5534-09-8, Beclomethasone
dipropionate 5874-97-5, Metaproterenol sulfate 7683-59-2,
Isoproterenol 9002-60-2, ACTH, biological studies 9004-10-8,
Insulin, biological studies 11056-06-7, Bleomycin 13010-47-4,
Lomustine 15663-27-1, Cisplatin 15826-37-6, Cromolyn sodium
18559-94-9, Albuterol 20830-81-3, Daunorubicin 22254-24-6,
Ipratropium bromide 22916-47-8, Miconazole 23031-25-6,
Terbutaline 23214-92-8 25953-19-9, Cefazolin 29122-68-7,
Atenolol 30392-40-6, Bitolterol 30516-87-1 32986-56-4,
Tobramycin 33419-42-0 35607-66-0, Cefoxitin 36791-04-5
37517-28-5, Amikacin 38677-81-5, Pirbuterol 50370-12-2,
Cefadroxil 51333-22-3, Budesonide 53643-48-4, Vindesine
59277-89-3, Acyclovir 61477-96-1, Piperacillin 62571-86-2,
Captopril 63527-52-6, Cefotaxime 64952-97-2, Moxalactam
69049-73-6, Nedocromil 72301-79-2, Enviroxime 72332-33-3,
Procaterol 75847-73-3, Enalapril 82410-32-0, Ganciclovir
89365-50-4, Salmeterol ***90566-53-3***
(pharmaceutical liposomes contg. cholesterol and salt of
cholesterol ester and)

IT 57-88-5, Cholesterol, biological studies
(pharmaceutical liposomes contg. cholesterol ester salts and)

L4 ANSWER 4 OF 5 COPYRIGHT 1992 ACS

AN CA110(20):179552w

TI Formulations containing fluticasone propionate for treatment of
bowel diseases

AU Richards, David Anthony

CS Glaxo Group Ltd.

LO UK

20 2015-11-16 2015-11-16 17

H; R2R7 = CH2; R3 = H, Cl, F; R4 = H, F; R5 = R6 = H; R5R6 = bond)
 were prep'd. Thus, I (R = CH2Cl, R1 = COEt, R2 = .beta.-Me, R3 = F,
 R4 = H, R5R6 = bond, R7 = H) was prep'd. by treating the
 corresponding 17-carboxylic acid with Me2NCSCl, hydrolyzing to the
 17-thiocarboxylic acid, and esterifying with BrCH2Cl.
 KW halomethyl androstanecarbothioate; antiinflammatory halomethyl
 androstanecarbothioate
 IT Inflammation inhibitors and Antiarthritics
 (halomethyl androstanecarbothioates)
 IT 28416-82-2 37927-29-0
 (acylation of)
 IT 53-34-9 338-95-4 2282-51-1
 (oxidn. of)
 IT 80473-87-6P 80473-92-3P 80474-39-1P 80486-66-4P 80486-69-7P
 (prepn. and acylation of)
 IT 80473-82-1P 80474-61-9P 80474-66-4P 80474-67-5P 80474-73-3P
 80474-74-4P
 (prepn. and chlorination of)
 IT 80486-68-6P
 (prepn. and collagen exchange of)
 IT 80473-96-7P
 (prepn. and deacylation of)
 IT 80473-84-3P
 (prepn. and elimination of oxygen from)
 IT 80473-85-4P 80473-88-7P 80474-34-6P 80474-38-0P 80474-43-7P
 80474-45-9P
 (prepn. and esterification of)
 IT 80474-11-9P 80483-93-8P
 (prepn. and fluorination of)
 IT 80474-33-5P 80474-37-9P 80474-50-6P 80474-51-7P 80474-52-8P
 80474-53-9P 80474-54-0P 80474-55-1P 80474-56-2P 80474-57-3P
 80474-58-4P 80474-59-5P 80474-60-8P
 (prepn. and hydrolysis of)
 IT 80473-97-8P
 (prepn. and oxidn. of)
 IT 37927-23-4P
 (prepn. and reaction of, with dimethylthiocarbamoyl chloride)
 IT 80474-00-6P 80474-19-7P 80474-32-4P
 (prepn. and redn. of)
 IT 79578-10-2P 80473-90-1P
 (prepn. and thiolation of)
 IT 65429-42-7P 80473-83-2P 80473-86-5P 80473-89-8P 80473-91-2P
 80473-93-4P 80473-94-5P 80473-95-6P 80473-98-9P 80473-99-0P
 80474-01-7P 80474-02-8P 80474-03-9P 80474-04-0P 80474-05-1P
 80474-06-2P 80474-07-3P 80474-08-4P 80474-09-5P 80474-10-8P
 80474-12-0P 80474-13-1P ***80474-14-2P*** 80474-15-3P
 80474-16-4P 80474-17-5P 80474-18-6P 80474-20-0P 80474-21-1P
 80474-22-2P 80474-23-3P 80474-24-4P 80474-25-5P 80474-26-6P
 80474-27-7P 80474-28-8P 80474-29-9P 80474-30-2P 80474-31-3P
 80474-35-7P 80474-36-8P 80474-40-4P 80474-41-5P 80474-42-6P
 80474-44-8P 80474-46-0P 80474-47-1P 80474-48-2P 80474-49-3P
 80474-62-0P 80474-63-1P 80474-64-2P 80474-65-3P 80474-68-6P
 80474-69-7P 80474-70-0P 80474-71-1P 80474-72-2P 80483-94-9P
 80486-67-5P 80486-70-0P 80486-71-1P
 (prepn. of)
 IT 16420-13-6
 (reaction of, with androstanecarboxylic acids)
 IT 3800-28-0 52510-14-2 65751-34-0
 (reaction of, with dimethylthiocarbamoylchloride)
 IT 28416-82-2 37926-75-3 37927-06-3 59861-01-7
 (thiolation of)

FLUTICASONE + ASTHMA

TI Hydrofluorocarbon propellants for pharmaceutical aerosols
AU Steele, Gerald; Somani, Asit; Lim, Joseph Geok Puan
CS Fisons PLC
LO UK
SO PCT Int. Appl., 18 pp.
PI WO 9111173 A1 8 Aug 1991
DS W: CA, JP, US
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, NL, SE
AI WO 91-GB133 30 Jan 1991
PRAI GB 90-2351 2 Feb 1990
GB 90-23655 31 Oct 1990
GB 90-26476 5 Dec 1990
IC ICM A61K009-12
ICS A61K009-72
SC 63-6 (Pharmaceuticals)
DT P
CO PIXXD2
PY 1991
LA Eng

L5 ANSWER 2 OF 3 COPYRIGHT 1992 ACS
AN CA115(14):142260b
TI Pharmaceutical inhalants containing a bronchodilator and a steroidal
anti-inflammatory agent
AU Palmer, James Barry Douglas
CS Glaxo Group Ltd.
LO UK
SO Eur. Pat. Appl., 8 pp.
PI EP 416951 A1 13 Mar 1991
DS R: AT, DE, DK, ES, GR, LU, NL, SE
AI EP 90-309846 7 Sep 1990
PRAI GB 89-20392 8 Sep 1989
GB 89-23644 20 Oct 1989
IC ICM A61K031-57
ICI A61K031-57, A61K031-135
SC 63-6 (Pharmaceuticals)
DT P
CO EPXXDW
PY 1991
LA Eng

L5 ANSWER 3 OF 3 COPYRIGHT 1992 ACS
AN CA114(20):192593n
TI Nonphospholipid pharmaceutical liposomes
AU Radhakrishnan, Ramachandran
CS Liposome Technology, Inc.
LO USA
SO PCT Int. Appl., 96 pp.
PI WO 9006775 A1 28 Jun 1990
DS W: AU, DK, FI, JP, NO
RW: AT, BE, CH, DE, ES, FR, GB, IT, LU, NL, SE
AI WO 89-US5525 6 Dec 1989
PRAI US 88-284158 14 Dec 1988
US 88-284216 14 Dec 1988
IC A61K043-00; A61K049-00; A61K037-22
SC 63-6 (Pharmaceuticals)
SX 1
DT P
CO PIXXD2
PY 1990
LA Eng

FLUTICASON
+ SALEM
SALMETEROL

L9 ANSWER 1 OF 3 COPYRIGHT 1992 ACS

CA115(14):142260b
TI Hydrofluorocarbon propellants for pharmaceutical aerosols
AU Steele, Gerald; Somani, Asit; Lim, Joseph Geok Paan
CS Fisons PLC
LO UK
SO PCT Int. Appl., 18 pp.
PI WO 9111173 A1 8 Aug 1991
DS W: CA, JP, US
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, NL, SE
AI WO 91-GB133 30 Jan 1991
PRAI GB 90-2351 2 Feb 1990
GB 90-23655 31 Oct 1990
GB 90-26476 5 Dec 1990
IC ICM A61K009-12
ICS A61K009-72
SC 63-6 (Pharmaceuticals)
DT P
CO PIXXD2
PY 1991
LA Eng

L9 ANSWER 2 OF 3 COPYRIGHT 1992 ACS
AN CA115(14):142260b
TI Pharmaceutical inhalants containing a bronchodilator and a steroidal
anti-inflammatory agent
AU Palmer, James Barry Douglas
CS Glaxo Group Ltd.
LO UK
SO Eur. Pat. Appl., 8 pp.
PI EP 416951 A1 13 Mar 1991
DS R: AT, DE, DK, ES, GR, LU, NL, SE
AI EP 90-309846 7 Sep 1990
PRAI GB 89-20392 8 Sep 1989
GB 89-23644 20 Oct 1989
IC ICM A61K031-57
ICI A61K031-57, A61K031-135
SC 63-6 (Pharmaceuticals)
DT P
CO EPXXDW
PY 1991
LA Eng

L9 ANSWER 3 OF 3 COPYRIGHT 1992 ACS
AN CA114(20):192593n
TI Nonphospholipid pharmaceutical liposomes
AU Radhakrishnan, Ramachandran
CS Liposome Technology, Inc.
LO USA
SO PCT Int. Appl., 96 pp.
PI WO 9006775 A1 28 Jun 1990
DS W: AU, DK, FI, JP, NO
RW: AT, BE, CH, DE, ES, FR, GB, IT, LU, NL, SE
AI WO 89-US5525 6 Dec 1989
PRAI US 88-284158 14 Dec 1988
US 88-284216 14 Dec 1988
IC A61K043-00; A61K049-00; A61K037-22
SC 63-6 (Pharmaceuticals)
SX 1
DT P
CO PIXXD2
PY 1990
LA Eng

**FLUTICASONE +
SALBUTAMOL**

L10 ANSWER 1 OF 2 COPYRIGHT 1992 ACS
CA115(14):142260b

TI Hydrofluorocarbon propellants for pharmaceutical aerosols
 AU Steele, Gerald; Somani, Asit; Lim, Joseph Geok Puan
 CS Fisons PLC
 LO UK
 SO PCT Int. Appl., 18 pp.
 PI WO 9111173 A1 8 Aug 1991
 DS W: CA, JP, US
 RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, NL, SE
 AI WO 91-GB133 30 Jan 1991
 PRAI GB 90-2351 2 Feb 1990
 GB 90-23655 31 Oct 1990
 GB 90-26476 5 Dec 1990
 IC ICM A61K009-12
 ICS A61K009-72
 SC 63-6 (Pharmaceuticals)
 DT P
 CO PIXXD2
 PY 1991
 LA Eng

L10 ANSWER 2 OF 2 COPYRIGHT 1992 ACS
 AN CA114(20):192593n
 TI Nonphospholipid pharmaceutical liposomes
 AU Radhakrishnan, Ramachandran
 CS Liposome Technology, Inc.
 LO USA
 SO PCT Int. Appl., 96 pp.
 PI WO 9006775 A1 28 Jun 1990
 DS W: AU, DK, FI, JP, NO
 RW: AT, BE, CH, DE, ES, FR, GB, IT, LU, NL, SE
 AI WO 89-US5525 6 Dec 1989
 PRAI US 88-284158 14 Dec 1988
 US 88-284216 14 Dec 1988
 IC A61K043-00; A61K049-00; A61K037-22
 SC 63-6 (Pharmaceuticals)
 SX 1
 DT P
 CO PIXXD2
 PY 1990
 LA Eng

=> d his

(FILE 'HOME' ENTERED AT 12:43:14 ON 06 MAR 92)
 SET COST OFF

FILE 'REGISTRY' ENTERED AT 12:47:20 ON 06 MAR 92
 E FLUTICASONE/CN

L1 1 S E3
 L2 1 S E4

FILE 'REGISTRY' ENTERED AT 12:48:29 ON 06 MAR 92
 1 S E5

FILE 'CA' ENTERED AT 12:49:40 ON 06 MAR 92

L4 5 S (FLUTICASONE#/IA OR L1 OR L2 OR L3)
 L5 3 S L4 AND (ASTHMA? OR INHAL? OR DOSE# OR 'AEROSOL?)/IA

FILE 'CA' ENTERED AT 12:51:09 ON 06 MAR 92

FILE 'REGISTRY' ENTERED AT 12:51:12 ON 06 MAR 92

L6 1 S SALMETEROL/CN
 L7 0 S SALBUTANOL/CN
 L8 1 S SALBUTANOL/CN

FILE 'CA' ENTERED AT 12:52:30 ON 06 MAR 92

17. 4,419,352, Dec. 6, 1983, Pyranoquinolinones and analogs thereof; David Cox, et al., 514/291, 232.5, 232.8, 826, 914, 925, 926, 927, 934; 544/126; 546/89, 92

18. 4,199,578, Apr. 22, 1980, Composition; Neil A. Stevenson, 514/171, 180

19. 4,045,439, Aug. 30, 1977, 6-Substituted-4-hydroxycinnolin-3-yl carboxylic acids and esters thereof; John Preston, et al., 544/235

20. 4,027,023, May 31, 1977, Cinnolin-3-yl carboxylic acids and derivatives; John Preston, et al., 514/248, 826; 544/235

=> s fluticasone

L6 2 FLUTICASONE

=> d 16 1-2

1. 4,985,418, Jan. 15, 1991, Pharmaceutical compositions; David A. Richards, 514/179, 180 [IMAGE AVAILABLE]

2. 4,906,476, Mar. 6, 1990, Novel liposome composition for sustained release of steroidal drugs in lungs; Ramachandran Radhakrishnan, 424/450, 1.1, 9 [IMAGE AVAILABLE]

=> s salmeterol and fluticasone

1 SALMETEROL

2 FLUTICASONE

L7 1 SALMETEROL AND FLUTICASONE

=> d 17 1

1. 4,906,476, Mar. 6, 1990, Novel liposome composition for sustained release of steroidal drugs in lungs; Ramachandran Radhakrishnan, 424/450, 1.1, 9 [IMAGE AVAILABLE]

=> s salmeterol and beclomethasone

1 SALMETEROL

150 BECLOMETHASONE

L8 1 SALMETEROL AND BECLOMETHASONE

=> d 18 1

1. 4,906,476, Mar. 6, 1990, Novel liposome composition for sustained release of steroidal drugs in lungs; Ramachandran Radhakrishnan, 424/450, 1.1, 9 [IMAGE AVAILABLE]

=> s beclomethasone/clm

L9 35 BECLOMETHASONE/CLM

=> d 19 1-35

1. 4,957,744, Sep. 18, 1990, Cross-linked esters of hyaluronic acid; Francesco della Valle, et al., 424/401, 423, 443, 451, 489; 512/5; 514/54, 844, 880; 536/55.1 [IMAGE AVAILABLE]

2. 4,927,400, May 22, 1990, Electrotransport transdermal system; Ronald P. Haak, et al., 604/20; 128/798 [IMAGE AVAILABLE]

3. 4,913,892, Apr. 3, 1990, Preparation and use of new solvates of beclomethasone 17,21-dipropionate; Philip R. Page, et al., 424/45; 514/180; 552/574

4. 4,906,476, Mar. 6, 1990, Novel liposome composition for sustained release of steroidal drugs in lungs; Ramachandran Radhakrishnan, 424/450, 1.1, 9

=> s 14 and beclomethasone
150 BECLOMETHASONE
L5 20 L4 AND BECLOMETHASONE

=> d 15 1-20

1. 4,912,131, Mar. 27, 1990, 4,7-diacyloxybenzofuran derivatives; Julian Adams, et al., 514/464, 320, 422, 452, 456, 469, 470; 546/196; 548/525; 549/362, 398, 435, 466, 467, 470
2. 4,906,654, Mar. 6, 1990, Cyclohept[blindolealkanoic acids, pharmaceutical compositions and use; John W. Gillard, et al., 514/411; 548/439, 448
3. 4,895,719, Jan. 23, 1990, Method and apparatus for administering dehydrated liposomes by inhalation; Ramachandran Radhakrishnan, et al., 424/45; 514/958, 959; 604/140
4. 4,866,051, Sep. 12, 1989, Micronised ~~beclomethasone~~ dipropionate monohydrate compositions and methods of use; John H. Hunt, et al., 514/180, 826
5. 4,863,073, Sep. 5, 1989, Valve for aerosol container; Peter C. W. Burt, et al., 222/402.2, 453
6. 4,841,964, Jun. 27, 1989, Inhaler; Wilhelm Hurka, et al., 128/203.15, 203.23; 604/58
7. 4,829,996, May 16, 1989, Apparatus for producing a spray of droplets of a liquid; Timothy J. Noakes, et al., 128/200.14; 239/706
8. 4,814,161, Mar. 21, 1989, Drug-containing chlorofluorocarbon aerosol propellant formulations; Philip A. Jinks, et al., 424/45; 514/78, 95, 99, 149, 183, 255, 315, 506, 558, 740, 743, 762, 767, 786, 937
9. 4,811,731, Mar. 14, 1989, Devices for administering medicaments to patients; Robert E. Newell, et al., 128/203.15; 604/58
10. 4,778,805, Oct. 18, 1988, 4,7-benzofurandione derivatives useful as inhibitors of leukotriene synthesis; Julian Adams, et al., 514/320, 422, 452, 456, 464, 469, 470; 546/196; 548/525; 549/362, 398, 435, 466, 467, 468, 469, 470
11. 4,778,673, Oct. 18, 1988, Additive-containing paints; Giorgio Vernizzi, et al., 424/10; 514/826, 922, 957, 958, 974
12. 4,778,054, Oct. 18, 1988, Pack for administering medicaments to patients; Robert E. Newell, et al., 206/531, 469, 532, 538, 540
13. 4,775,680, Oct. 4, 1988, Cyclohept[blindolealkanoic acids, pharmaceutical compositions and use; John W. Gillard, et al., 514/411; 548/439, 448
14. 4,758,433, Jul. 19, 1988, Oil extract of Tanacetum parthenium for treating migraine; Edward S. Johnson, et al., 424/195.1; 514/468; 549/299
15. 4,627,432, Dec. 9, 1986, Devices for administering medicaments to patients; Robert E. Newell, et al., 128/203.15, 200.19, 203.21; 221/30; 222/88; 604/58
16. 4,590,206, May 20, 1986, Inhalation pharmaceuticals; Raymond B. Forrester, et al., 514/456, 826, 951

IMAGE AVAILABLE]

5. 4,904,474, Feb. 27, 1990, Delivery of drug to colon by oral disage form; Felix Theeuwes, et al., 424/424, 426, 468
6. 4,895,719, Jan. 23, 1990, Method and apparatus for administering dehydrated liposomes by inhalation; Ramachandran Radhakrishnan, et al., 424/45; 514/958, 959; 604/140
7. 4,885,293, Dec. 5, 1989, Antiglaucoma agents; David R. Andrews, et al., 514/223.2, 19, 171, 223.5, 913
8. 4,879,274, Nov. 7, 1989, External medication for skin; Tetsuro Kamiya, et al., 514/12; 424/449; 514/29, 31, 39, 52, 110, 152, 154, 167, 174, 178, 179, 180, 182, 258, 270, 271, 274, 280, 282, 295, 301, 312, 356
9. 4,866,051, Sep. 12, 1989, Micronised beclomethasone dipropionate monohydrate compositions and methods of use; John H. Hunt, et al., 514/180, 826
10. 4,851,521, Jul. 25, 1989, Esters of hyaluronic acid; Francesco della Valle, et al., 536/55.1; 424/423, 443, 489; 514/54, 844, 880
11. 4,844,902, Jul. 4, 1989, Topically applicable formulations of gyrase inhibitors in combination with corticosteroids; Klaus Grohe, 424/449, 447
IMAGE AVAILABLE]
12. 4,840,772, Jun. 20, 1989, Antiglaucoma compositions and methods; Robert Watkins, et al., 422/61; 435/810; 436/808
13. 4,835,142, May 30, 1989, Powdery pharmaceutical composition suitable for application to mucosa of oral or nasal cavity; Yoshiki Suzuki, et al., 514/53, 180
14. 4,814,161, Mar. 21, 1989, Drug-containing chlorofluorocarbon aerosol propellant formulations; Philip A. Jinks, et al., 424/45; 514/78, 95, 99, 149, 183, 255, 315, 506, 558, 740, 743, 762, 767, 786, 937
15. 4,810,488, Mar. 7, 1989, Physically modified beclomethasone dipropionate suitable for use in aerosols; Philip A. Jinks, 424/45; 552/574
16. 4,783,444, Nov. 8, 1988, Antiglaucoma compositions and methods; Robert Watkins, et al., 514/19, 912, 913, 914
17. 4,778,673, Oct. 18, 1988, Additive-containing paints; Giorgio Vernizzi, et al., 424/10; 514/826, 922, 957, 958, 974
18. 4,778,054, Oct. 18, 1988, Pack for administering medicaments to patients; Robert E. Newell, et al., 206/531, 469, 532, 538, 540
19. 4,765,983, Aug. 23, 1988, Adhesive medical tapes for oral mucosa; Hitoshi Takayanagi, et al., 424/434, 435, 449
20. 4,579,960, Apr. 1, 1986, Stable solutions containing thimerosal; Pui-Ho Yuen, et al., 556/2; 514/496
21. 4,478,822, Oct. 23, 1984, Drug delivery system utilizing thermosetting gels; John L. Haslam, et al., 424/78, 85.4, 94.3, 114, 116; 514/10, 11, 39, 45, 46, 54, 56, 152, 158, 162, 171, 179, 199, 203, 206, 218, 221, 263, 304, 420, 535, 788, 912
22. 4,474,752, Oct. 2, 1984, Drug delivery system utilizing thermosetting gels; John L. Haslam, et al., 434/78; 424/78, 85.4, 94.3, 114, 116; 514/39,

152, 162, 179, 357, 401, 472, 593, 822, 825, 826, 866, 906, 944

23. 4,414,209, Nov. 8, 1983, Micronized aerosol steroids; Peter B. Cook, et al., 514/180, 826, 958; 552/503, 529, 572, 574, 580, 581

24. 4,370,322, Jan. 25, 1983, Topically administrable pharmaceutical compositions containing anti-inflammatory steroids; Michael J. Russe, et al., 514/180, 887

25. 4,364,923, Dec. 21, 1982, Chemical compounds; Peter B. Cook, et al., 424/46, 45; 514/179

26. 4,350,690, Sep. 21, 1982, Steroid composition; Cyrus R. Kumana, 514/180, 925

27. 4,347,236, Aug. 31, 1982, Process for the preparation of a mixture of an anti-inflammatory steroid and a fluoro-chloro-hydrocarbon to be used as a propellant; Paavo T. Tanskanen, 424/45; 514/179

28. 4,343,798, Aug. 10, 1982, Topical antimicrobial anti-inflammatory compositions; Mahdi B. Fawzi, 514/179, 180, 887

29. 4,333,927, Jun. 8, 1982, Skin preparation; Kunihiro Ofuchi, et al., 514/174, 179, 180

30. 4,294,829, Oct. 13, 1981, Powdery pharmaceutical composition and powdery preparation for application to the nasal mucosa, and method for administration thereof; Yoshiki Suzuki, et al., 514/174, 180, 357, 401, 420, 428, 456, 653, 951

31. 4,225,597, Sep. 30, 1980, Beclomethasone dipropionate-hexane solvate and aerosols prepared therefrom; Lawrence E. Finckler, 514/45, 957

32. 4,199,578, Apr. 22, 1980, Composition; Neil A. Stevenson, 514/171, 180

33. 4,044,126, Aug. 23, 1977, Steroidal aerosol compositions and process for the preparation thereof; Peter Barry Cook, et al., 514/180, 957

34. 4,041,055, Aug. 9, 1977, Process for the preparation of 17.alpha.-hydroxyprogesterones and corticoids from androstenes; Kenneth Paul Shephard, et al., 552/531; 540/112; 552/572, 573, 574, 576, 577, 580, 581, 595, 596, 597, 598, 639

35. 3,891,631, Jun. 24, 1975, Process for preparing 17.alpha.-monoesters of 17.alpha., 21-dihydroxy-20-oxo steroids; Gordon Hanley Phillipps, et al., 540/112; 552/506, 507, 534, 538, 573, 574, 576, 577, 581, 595

=> s 19 and inhalation/clm

988 INHALATION/CLM

L10 9 L9 AND INHALATION/CLM

=> d 110 1-9

1. 4,906,476, Mar. 6, 1990, Novel liposome composition for sustained release of steroidal drugs in lungs; Ramachandran Radhakrishnan, 424/450, 1.1, 9
[IMAGE AVAILABLE]

2. 4,866,051, Sep. 12, 1989, Micronised beclomethasone dipropionate monohydrate compositions and methods of use; John H. Hunt, et al., 514/180, 826

3. 4,810,488, Mar. 7, 1989, Physically modified beclomethasone dipropionate

4. 4,414,209, Nov. 8, 1983, Micronized aerosol steroids; Peter B. Cook, et al., 514/180, 826, 958; 552/503, 529, 572, 574, 580, 581
5. 4,364,923, Dec. 21, 1982, Chemical compounds; Peter B. Cook, et al., 424/46, 45; 514/179
6. 4,347,236, Aug. 31, 1982, Process for the preparation of a mixture of an anti-inflammatory steroid and a fluoro-chloro-hydrocarbon to be used as a propellant; Paavo T. Tanskanen, 424/45; 514/179
7. 4,225,597, Sep. 30, 1980, Beclomethasone dipropionate-hexane solvate and aerosols prepared therefrom; Lawrence E. Fincknor, 514/45, 957
8. 4,199,578, Apr. 22, 1980, Composition; Neil A. Stevenson, 514/171, 180
9. 4,044,126, Aug. 23, 1977, Steroidal aerosol compositions and process for the preparation thereof; Peter Barry Cook, et al., 514/180, 957